Germany’s Evotec Gets Takeover Interest From Halozyme
(Bloomberg) — Germany’s Evotec SE is attracting potential takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc., people familiar with the matter said. Most Read from Bloomberg Halozyme has recently expressed interest in acquiring Evotec at about €11 per share, the people said, asking not to be identified because the information is private. That would…